Antineoplastic interferons

Introduction

Interferons (IFNs) are naturally occurring cytokines secreted by host cells in response to viral infections, tumors, and other immune stimuli. They belong to the cytokine family of glycoproteins and possess antiviral, antiproliferative, and immunomodulatory properties. Recombinant technology has enabled the production of interferons for therapeutic use in cancer, viral diseases, and certain immune disorders.

As antineoplastic agents, interferons exert their effect by inhibiting tumor cell proliferation, enhancing immune recognition of malignant cells, and modulating oncogene expression. They have been incorporated into cancer therapy regimens since the 1980s, although their role has diminished somewhat with the advent of targeted therapies and immune checkpoint inhibitors.

---

Classification of Interferons

Interferons are categorized into three main types:

1. Type I interferons

   • Interferon-α (IFN-α): multiple subtypes used therapeutically.

   • Interferon-β (IFN-β) (more relevant to multiple sclerosis than cancer).

2. Type II interferons

   • Interferon-γ (IFN-γ): limited use in cancer; mainly in immunodeficiencies.

3. Type III interferons

   • Interleukin-28/29 (IFN-λ): experimental, not widely used in oncology.

Antineoplastic interferons primarily involve IFN-α preparations.

---

Generic Names and Formulations

Interferon-α formulations

• Interferon alfa-2a

• Interferon alfa-2b

• Peginterferon alfa-2a (pegylated)

• Peginterferon alfa-2b (pegylated)

• Roferon-A (brand, interferon alfa-2a)

• Intron-A (brand, interferon alfa-2b)

Interferon-γ formulation

• Interferon gamma-1b (Actimmune®)

---

Mechanism of Action

Antineoplastic interferons work via multiple mechanisms:

1. Antiproliferative effects

   • Inhibit cell cycle progression by upregulating cell cycle inhibitors.

   • Induce apoptosis in malignant cells.

2. Immunomodulation

   • Increase expression of major histocompatibility complex (MHC) molecules on tumor cells → enhances recognition by cytotoxic T lymphocytes.

   • Activate natural killer (NK) cells, macrophages, and T-cells against tumor cells.

3. Anti-angiogenic effects

   • Suppress angiogenesis by reducing pro-angiogenic factors (e.g., VEGF).

4. Oncogene modulation

   • Downregulate oncogene expression, altering tumor cell behavior.

---

Clinical Uses in Oncology

1. Hematologic malignancies

• Hairy cell leukemia (HCL)

  • IFN-α was historically the standard treatment before purine analogues (cladribine, pentostatin) became preferred. Still used in some refractory cases.

• Chronic myeloid leukemia (CML)

  • IFN-α was used before tyrosine kinase inhibitors (e.g., imatinib). May still have a role in selected patients who cannot tolerate TKIs.

• Multiple myeloma

  • IFN-α sometimes used as maintenance therapy, though largely replaced by modern agents (lenalidomide, bortezomib).

• Non-Hodgkin lymphoma (NHL)

  • IFN-α has been used as adjunct therapy, particularly in low-grade lymphomas.

2. Solid tumors

• Renal cell carcinoma (RCC)

  • IFN-α was a standard systemic therapy before the advent of tyrosine kinase inhibitors and immune checkpoint inhibitors. It is now rarely used but may be combined with other agents in select cases.

• Melanoma

  • High-dose IFN-α has been used as adjuvant therapy after surgical resection of high-risk melanoma. It improves relapse-free survival but with substantial toxicity.

• Kaposi’s sarcoma (HIV-associated)

  • IFN-α has demonstrated efficacy, especially in patients with intact immune function.

3. Other cancers (limited or historical use)

• Bladder cancer (adjunct to BCG therapy in some protocols).

• Ovarian and cervical cancers (investigational use).

---

Dosage Examples

• Hairy cell leukemia: IFN-α 2 million IU subcutaneously three times weekly.

• CML: IFN-α 5 million IU/m²/day subcutaneously.

• Melanoma (adjuvant high-dose therapy):

  • Induction: 20 million IU/m² IV, 5 days/week for 4 weeks.

  • Maintenance: 10 million IU/m² SC three times/week for 48 weeks.

• Renal cell carcinoma: 5–20 million IU subcutaneously three times weekly.

• Kaposi’s sarcoma: 30 million IU/day SC, adjusted based on tolerance.

Pegylated interferons are given once weekly due to extended half-life.

---

Contraindications

• Hypersensitivity to interferons.

• Severe psychiatric disorders (depression, suicidal ideation).

• Autoimmune diseases (risk of exacerbation).

• Severe cardiac disease (arrhythmias, decompensated heart failure).

• Decompensated liver disease.

• Pregnancy (abortifacient potential).

---

Adverse Effects

Common (flu-like symptoms)

• Fever, chills, myalgia, fatigue (usually transient, prominent after initial doses).

Hematologic

• Leukopenia, thrombocytopenia, anemia.

Neuropsychiatric

• Depression, irritability, insomnia, cognitive dysfunction, suicidal thoughts.

Gastrointestinal

• Anorexia, nausea, vomiting, weight loss.

Hepatic

• Elevated liver enzymes, hepatitis.

Dermatologic

• Alopecia, injection site reactions.

Endocrine/Metabolic

• Thyroid dysfunction (hypothyroidism or hyperthyroidism).

• Rarely, diabetes mellitus induction.

Cardiovascular

• Hypotension, arrhythmias, cardiomyopathy (rare).

---

Precautions

• Monitoring:

  • CBC, liver function, renal function every 2–4 weeks initially.

  • Thyroid function tests periodically.

  • Psychiatric evaluation before and during therapy.

• Psychiatric history: Avoid or use cautiously in patients with depression.

• Elderly patients: More prone to severe side effects.

• Combination therapy: May potentiate toxicity when combined with cytotoxic chemotherapy.

---

Drug Interactions

• Myelosuppressive drugs: Additive risk of bone marrow suppression (e.g., cytarabine, cyclophosphamide).

• Antidepressants/psychiatric medications: May interact with IFN-induced neuropsychiatric effects.

• Hepatotoxic agents: Increased risk of liver injury.

• Theophylline: IFN-α may reduce clearance → increased toxicity.

• Warfarin and anticoagulants: Interferons may alter coagulation parameters, requiring closer monitoring.

---

Comparative Role in Oncology

• Past decades: Interferons represented one of the few systemic immunotherapies available, widely used in CML, RCC, and melanoma.

• Current practice: Their role has largely declined with the introduction of TKIs, immune checkpoint inhibitors, and targeted therapies that show superior efficacy and tolerability.

• Still relevant in select settings: Hairy cell leukemia (limited), adjuvant melanoma (in resource-limited regions), Kaposi’s sarcoma, and certain hematologic malignancies where modern therapies are unavailable or unsuitable.